Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials.

Conclusion: Secukinumab improved clinical outcomes and was well tolerated in patients with concomitant baseline comorbid conditions. PMID: 33023357 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33023357?dopt=Abstract

Source: Journal of Dermatological Treatment - October 9, 2020 Category: Dermatology Tags: J Dermatolog Treat Source Type: research